Protocol · Herbal · 03

The Buhner Protocol

A plant-based system for Lyme and its coinfections, built from decades of phytochemical research by the late herbalist Stephen Harrod Buhner.

Stephen Harrod Buhner approached Lyme disease as a complex, stealth-pathogen ecology rather than a single infection. His protocols are organized around two ideas: directly antimicrobial herbs that cross the blood-brain barrier, and cytokine-modulating herbs that interrupt the damage Borrelia provokes in collagen, joints, and neural tissue.

“The borrelia are not the disease. The cytokine cascade they provoke is.”
— Healing Lyme, 2nd ed.
Foundation

The Core Protocol

The core protocol is usually built up over two to three weeks to minimise herxheimer reactions. Doses are illustrative — work with a clinician for your situation.

HerbTypical doseRolePubMed
Japanese Knotweed (Polygonum cuspidatum)1 tsp tincture 3–6×/day, titrated upCytokine modulator, crosses BBB, broad antispirochetalPMID 16205932
Cat's Claw (Uncaria tomentosa, TOA-free)1–3 g powder 2×/dayImmunomodulation, antispirochetal in vitroPMID 21961013
Andrographis paniculata400 mg standardized 3–4×/dayCardio-protective, CNS penetration, antispirochetalPMID 31610053
Astragalus (early stage only)1000 mg/dayTh1 immune support; avoid in chronic stagesPMID 25060277
Stephania root1/4–1/2 tsp tincture 3×/dayReduces neuroinflammation, blocks NMDA cascadePMID 29853020
Layered

Coinfection Extensions

Buhner published dedicated volumes for the major Lyme coinfections. The herbs below are added onto the core protocol, not in place of it.

  • Babesia
    Cryptolepis sanguinolenta · Sida acuta · Alchornea cordifolia · Artemisia annua
  • Bartonella
    Houttuynia cordata · Sida acuta · Japanese knotweed · EGCG / green tea
  • Ehrlichia / Anaplasma
    Cordyceps · Sida acuta · Cryptolepis · Houttuynia
  • Mycoplasma
    Cordyceps · Houttuynia · Isatis · Olive leaf
  • Rickettsia
    Cryptolepis · Sida acuta · Houttuynia

Notes on use

Buhner emphasised tincture quality, slow titration, and reassessment every 30–60 days. Most patients run the protocol for a minimum of eight months; those with neurological involvement often longer.